

# Skipper

Refer to important disclosures at the end of this report

## Strong performance, muted outlook for Polymer segment

- Skipper's operational performance exceeded our expectations.** Revenues increased by 33% yoy aided by strong volume growth and rising commodity prices. Though the EBITDAM declined by 64bps yoy to 13.1%, PAT increased by 31% yoy.
  - While engineering products (EP) reported robust growth at 29% yoy, the polymer segment lagged behind with muted growth of 6% yoy largely impacted by GST related disruptions.**
  - Order inflows was at ~Rs5.25bn while the backlog stood at Rs25bn.** The company's JV with MetzerPlas - Israeli kibbutz-based industry of micro-irrigation products is likely to be finalised in 4QFY18.
  - Though the management was upbeat on the performance in the EP segment, the guidance on polymer segment was muted.** We have downgraded FY18/19/20E EPS by 8% / 6% and 6% respectively on lower revenue and profitability assumptions in the polymer segment. Maintain BUY with price target of Rs297 (SoTP based)
- Robust performance:** Skipper reported revenues at Rs 5.6bn (+33% yoy). Though the gross margins declined by 203bps to 31%, the EBITDAM declined by 64bps to 13.1%. PAT increased by 31% yoy to Rs292mn. Revenues in the EP segment increased by 29% yoy to Rs4.9bn –aided by volume growth and rising commodity prices (~8-10%). EBITM in the EP segment increased by 42bps to 13.1%. Revenues in the polymer segment grew at a meagre 6% yoy to Rs540 mn as GST related disruptions continue to impact offtake from distributors and dealers. EBITM increased by 46bps yoy to 6.7%. Order inflows worth Rs5.3bn was secured from PGCIL, SEB's and Reliance Jio. Order back log stands strong at ~Rs26bn.
  - Maintain BUY:** Strong order backlog of ~Rs25bn (1.7x FY17 Engineering product sales) coupled with steady order pipeline ensures robust revenue visibility in the EP segment over the next couple of years. Going forward, the company is also planning to increasingly bid for railway electrification projects. Management commentary indicate that GST related disruptions still persists and majority of dealers hesitate to replenish stocks – there is a possibility that the polymer pipe industry may report flattish growth in FY18. Also, few of the established players have expanded capacities, thereby impacting the utilisations across the industry. The company expects the polymer division to report ~10-15% growth in FY18 and ~ 50-55% growth in the subsequent two years. We have downgraded FY18/19/20E EPS by 8% / 6% and 6% respectively on lower revenue and profitability assumption in the polymer segment. We expect the company to post robust revenue and PAT growth (FY17-20 CAGR) of ~ 22% and ~25% respectively. We Maintain BUY with revised price target of Rs297 (SoTP based on FY20E earnings).

### Financial Snapshot (Standalone)

(Rs mn)	FY16	FY17	FY18E	FY19E	FY20E
Net Sales	15,062	17,030	20,360	25,063	31,095
EBITDA	2,192	2,460	2,646	3,292	4,071
EBITDA Margin (%)	14.6	14.4	13.0	13.1	13.1
APAT	951	1,115	1,218	1,650	2,177
EPS (Rs)	9.3	10.9	11.9	16.1	21.3
EPS (% chg)	6.7	17.3	9.2	35.5	31.9
ROE (%)	27.7	25.5	22.3	24.6	25.9
P/E (x)	25.5	21.7	19.9	14.7	11.1
EV/EBITDA (x)	12.9	11.4	10.8	8.7	7.0
P/BV (x)	6.4	4.9	4.1	3.3	2.6

Source: Company, Emkay Research

<b>CMP</b>	<b>Target Price</b>
Rs 237 as of (February 6, 2018)	Rs 297 (▼) 12 months
<b>Rating</b>	<b>Upside</b>
BUY (■)	25.3 %

### Change in Estimates

EPS Chg FY18E/FY19E (%)	(8.5)/(6.4)
Target Price change (%)	(9.2)
Target Period (Months)	12
Previous Reco	BUY

### Emkay vs Consensus

EPS Estimates		
	FY18E	FY19E
Emkay	11.9	16.1
Consensus	11.7	15.0
Mean Consensus TP (12M)	Rs 283	

### Stock Details

Bloomberg Code	SKIPPER IN
Face Value (Rs)	1
Shares outstanding (mn)	103
52 Week H/L	293 / 140
M Cap (Rs bn/USD bn)	24 / 0.38
Daily Avg Volume (nos.)	1,98,354
Daily Avg Turnover (US\$ mn)	0.8

### Shareholding Pattern Dec '17

Promoters	70.4%
FII's	6.2%
DII's	9.9%
Public and Others	13.6%

### Price Performance

(%)	1M	3M	6M	12M
<b>Absolute</b>	(11)	(11)	6	50
<b>Rel. to Nifty</b>	(11)	(11)	2	26

### Relative price chart



Source: Bloomberg

This report is solely produced by Emkay Global. The following person(s) are responsible for the production of the recommendation:

#### John Perinchery

 john.perinchery@emkayglobal.com  
 +91 22 66121374

#### Jason Soans

 jason.soans@emkayglobal.com  
 +91 22 66121262

## Exhibit 1: Actual V/s estimates for Quarter

(Rsmn)	Actual	Estimates		% variation		Comment
		Emkay	Consensus	Emkay	Consensus	
Sales	5,664	4,928	4,946	15%	15%	Better than expected execution in the EP segment
EBITDA	741	677	639	9%	16%	Lower margins in the polymer segment impacts EBITDAM. However the strong execution in the EP segment propels EBITDA.
EBITDA, margin	13.1%	14%	13%	-62 bps	18 bps	
PAT	292	235	240	24%	22%	Lower interest cost aids PAT growtha

Source: Company, Emkay Research

## Exhibit 2: Quarterly Financials-Standalone

Rs mn	Q3FY18	Q3FY17	Q2FY18	YoY (%)	QoQ (%)	YTD FY17	YTD FY18	YoY (%)
Revenues	5,664	4,251	5,156	33%	10%	11,002	14,809	35%
Material cost	3,902	2,843	3,458	37%	13%	7,141	9,830	38%
as % of sales	69%	67%	67%	203 bps	184 bps	65%	66%	147 bps
Employee Cost	236	194	251	22%	-6%	539	697	29%
as % of sales	4%	5%	5%	-40 bps	-72 bps	5%	5%	-19 bps
Other expenditure	786	632	765	24%	3%	1,610	2,342	45%
as % of sales	14%	15%	15%	-99 bps	-96 bps	15%	16%	118 bps
Total expenditure	4,923	3,668	4,473	34%	10%	9,290	12,869	39%
EBITDA	741	583	683	27%	8%	1,712	1,940	13%
Depreciation	118	76	121	54%	-2%	215	346	60%
EBIT	623	507	562	23%	11%	1,497	1,594	7%
Other Income	3	8	3	-59%	1%	23	14	-40%
Interest	176	190	200	-7%	-12%	535	545	2%
PBT	450	325	365	38%	23%	985	1,063	8%
Taxes	158	103	133	54%	19%	324	379	17%
Reported PAT	292	222	232	31%	26%	661	684	4%
Adjusted EPS	2.9	2.2	2.3	31%	26%	6.5	6.7	4%
<b>Margins (%)</b>				<b>bps</b>	<b>bps</b>			<b>bps</b>
Gross Margins	31.1%	33.1%	32.9%	(203)	(184)	35.1%	33.6%	(147)
EBIDTAM	13.1%	13.7%	13.2%	(64)	(17)	15.6%	13.1%	(246)
EBITM	11.0%	11.9%	10.9%	(93)	10	13.6%	10.8%	(284)
PBTM	7.9%	7.6%	7.1%	30	86	9.0%	7.2%	(178)
PATM	5.2%	5.2%	4.5%	(6)	65	6.0%	4.6%	(138)
Effective Tax rate	35.1%	31.7%	36.4%	345	(124)	32.9%	35.6%	271

Source: Company, Emkay Research

**Exhibit 3: Segmental performance-Standalone**

Rs in mn	Q3FY18	Q3FY17	Q2FY18	YoY (%)	QoQ (%)	YTD FY17	YTD FY18	YoY (%)
<b>Segment Revenue</b>								
Engineering Products	4,863	3,784	4,634	29%	5%	9,982	13,148	32%
PVC Products	540	508	428	6%	26%	1,387	1,401	1%
Infrastructure Projects	261	263	95	-1%	176%	496	599	21%
Total	5,664	4,555	5,156	24%	10%	11,866	15,148	28%
Less : inter segment revenue	-	-	-			-	-	
<b>Total</b>	<b>5,664</b>	<b>4,555</b>	<b>5,156</b>	<b>24%</b>	<b>10%</b>	<b>11,866</b>	<b>15,148</b>	<b>28%</b>
<b>Segment Results</b>								
Engineering Products	639	481	606	33%	5%	1,471	1,684	15%
PVC Products	36	32	28	14%	28%	107	95	-12%
Infrastructure Projects	32	37	11	-13%	185%	70	73	3%
Total	707	550	645	29%	9%	1,648	1,852	12%
Less- Unall (Exp)	84	43	83	97%	1%	152	258	70%
Add Other Income	3	8	3	-59%	1%	23	14	-40%
Less- Interest Exp	176	190	200	-7%	-12%	535	545	2%
Other Exceptional Item	-	-	-			-	-	
<b>PBT</b>	<b>450</b>	<b>325</b>	<b>365</b>	<b>38%</b>	<b>23%</b>	<b>985</b>	<b>1,063</b>	<b>8%</b>
<b>Segment Margins (%)</b>								
				bps	bps			bps
Engineering Products	13.1%	12.7%	13.1%	42	6	14.7%	12.8%	-192
PVC Products	6.7%	6.2%	6.6%	46	8	7.7%	6.8%	-96
Infrastructure Projects	12.3%	14.0%	11.9%	-173	38	14.2%	12.1%	-201
<b>Average</b>	<b>12.5%</b>	<b>12.1%</b>	<b>12.5%</b>	<b>41</b>	<b>-4</b>	<b>13.9%</b>	<b>12.2%</b>	<b>-167</b>

Source: Company, Emkay Research

**Exhibit 4: Revision in Earning Estimates**

Y/E, Mar (Rs. mn)	FY18E			FY19E			FY20E		
	Earlier	Revised	% Change	Earlier	Revised	% Change	Earlier	Revised	% Change
Revenues	20597	20,360	-1%	25889	25,063	-3%	32120	31,095	-3%
EBITDA	2803	2,646	-6%	3442	3,292	-4%	4278	4,071	-5%
EBITDAM (%)	13.6%	13.0%	-61 bps	13.3%	13.1%	-16 bps	13.3%	13.1%	-23 bps
APAT	1328	1,218	-8%	1756	1,650	-6%	2322	2,177	-6%
EPS (Rs)	13.0	11.9	-8%	17.2	16.1	-6%	22.7	21.3	-6%

Source: Company, Emkay Research

**Key Financials (Standalone)****Income Statement**

Y/E Mar (Rs mn)	FY16	FY17	FY18E	FY19E	FY20E
<b>Net Sales</b>	<b>15,062</b>	<b>17,030</b>	<b>20,360</b>	<b>25,063</b>	<b>31,095</b>
<b>Expenditure</b>	<b>12,870</b>	<b>14,569</b>	<b>17,714</b>	<b>21,771</b>	<b>27,023</b>
<b>EBITDA</b>	<b>2,192</b>	<b>2,460</b>	<b>2,646</b>	<b>3,292</b>	<b>4,071</b>
Depreciation	241	315	363	403	443
<b>EBIT</b>	<b>1,951</b>	<b>2,145</b>	<b>2,283</b>	<b>2,889</b>	<b>3,629</b>
Other Income	52	31	15	15	15
Interest expenses	570	611	558	547	534
<b>PBT</b>	<b>1,433</b>	<b>1,565</b>	<b>1,740</b>	<b>2,358</b>	<b>3,110</b>
Tax	482	450	522	707	933
Extraordinary Items	0	0	0	0	0
Minority Int./Income from Assoc.	0	0	0	0	0
<b>Reported Net Income</b>	<b>951</b>	<b>1,115</b>	<b>1,218</b>	<b>1,650</b>	<b>2,177</b>
<b>Adjusted PAT</b>	<b>951</b>	<b>1,115</b>	<b>1,218</b>	<b>1,650</b>	<b>2,177</b>

**Balance Sheet**

Y/E Mar (Rs mn)	FY16	FY17	FY18E	FY19E	FY20E
Equity share capital	102	102	102	102	102
Reserves & surplus	3,713	4,841	5,868	7,321	9,301
<b>Net worth</b>	<b>3,815</b>	<b>4,943</b>	<b>5,970</b>	<b>7,424</b>	<b>9,404</b>
<b>Minority Interest</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Loan Funds</b>	<b>4,504</b>	<b>4,159</b>	<b>4,500</b>	<b>4,500</b>	<b>4,400</b>
Net deferred tax liability	315	391	391	391	391
<b>Total Liabilities</b>	<b>8,634</b>	<b>9,493</b>	<b>10,861</b>	<b>12,315</b>	<b>14,195</b>
<b>Net block</b>	<b>3,852</b>	<b>4,642</b>	<b>5,179</b>	<b>5,526</b>	<b>5,834</b>
<b>Investment</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>	<b>0</b>
<b>Current Assets</b>	<b>7,651</b>	<b>8,524</b>	<b>10,005</b>	<b>11,889</b>	<b>14,469</b>
Cash & bank balance	498	249	273	109	61
Other Current Assets	0	0	0	0	0
<b>Current liabilities &amp; Provision</b>	<b>3,268</b>	<b>3,817</b>	<b>4,323</b>	<b>5,101</b>	<b>6,109</b>
<b>Net current assets</b>	<b>4,383</b>	<b>4,707</b>	<b>5,682</b>	<b>6,788</b>	<b>8,361</b>
Misc. exp	0	0	0	0	0
<b>Total Assets</b>	<b>8,634</b>	<b>9,493</b>	<b>10,861</b>	<b>12,315</b>	<b>14,195</b>

**Cash Flow**

Y/E Mar (Rs mn)	FY16	FY17	FY18E	FY19E	FY20E
<b>PBT (Ex-Other income) (NI+Dep)</b>	<b>1,381</b>	<b>1,534</b>	<b>1,725</b>	<b>2,343</b>	<b>3,095</b>
Other Non-Cash items	62	20	0	0	0
Chg in working cap	(1,208)	(496)	(952)	(1,271)	(1,620)
<b>Operating Cashflow</b>	<b>651</b>	<b>1,752</b>	<b>1,173</b>	<b>1,314</b>	<b>1,518</b>
Capital expenditure	(946)	(850)	(756)	(750)	(750)
<b>Free Cash Flow</b>	<b>(295)</b>	<b>903</b>	<b>416</b>	<b>564</b>	<b>768</b>
Investments	0	0	0	0	0
Other Investing Cash Flow	(25)	21	0	0	0
<b>Investing Cashflow</b>	<b>(919)</b>	<b>(797)</b>	<b>(741)</b>	<b>(735)</b>	<b>(735)</b>
Equity Capital Raised	0	0	0	0	0
Loans Taken / (Repaid)	1,073	(346)	341	0	(100)
Dividend paid (incl tax)	(160)	(172)	(191)	(197)	(197)
Other Financing Cash Flow	(215)	43	0	0	0
<b>Financing Cashflow</b>	<b>128</b>	<b>(1,087)</b>	<b>(407)</b>	<b>(744)</b>	<b>(831)</b>
<b>Net chg in cash</b>	<b>(140)</b>	<b>(132)</b>	<b>24</b>	<b>(165)</b>	<b>(48)</b>
Opening cash position	561	498	249	273	109
<b>Closing cash position</b>	<b>498</b>	<b>249</b>	<b>273</b>	<b>109</b>	<b>61</b>

Source: Company, Emkay Research

**Key Ratios**

<b>Profitability (%)</b>	<b>FY16</b>	<b>FY17</b>	<b>FY18E</b>	<b>FY19E</b>	<b>FY20E</b>
EBITDA Margin	14.6	14.4	13.0	13.1	13.1
EBIT Margin	13.0	12.6	11.2	11.5	11.7
Effective Tax Rate	33.6	28.8	30.0	30.0	30.0
Net Margin	6.3	6.5	6.0	6.6	7.0
ROCE	26.1	24.0	22.6	25.1	27.5
ROE	27.7	25.5	22.3	24.6	25.9
RoIC	28.1	25.5	23.2	25.4	27.6

<b>Per Share Data (Rs)</b>	<b>FY16</b>	<b>FY17</b>	<b>FY18E</b>	<b>FY19E</b>	<b>FY20E</b>
EPS	9.3	10.9	11.9	16.1	21.3
CEPS	11.6	14.0	15.5	20.1	25.6
BVPS	37.3	48.3	58.3	72.6	91.9
DPS	1.4	1.6	1.6	1.6	1.6

<b>Valuations (x)</b>	<b>FY16</b>	<b>FY17</b>	<b>FY18E</b>	<b>FY19E</b>	<b>FY20E</b>
PER	25.5	21.7	19.9	14.7	11.1
P/CEPS	20.3	17.0	15.3	11.8	9.3
P/BV	6.4	4.9	4.1	3.3	2.6
EV / Sales	1.9	1.7	1.4	1.1	0.9
EV / EBITDA	12.9	11.4	10.8	8.7	7.0
Dividend Yield (%)	0.6	0.7	0.7	0.7	0.7

<b>Gearing Ratio (x)</b>	<b>FY16</b>	<b>FY17</b>	<b>FY18E</b>	<b>FY19E</b>	<b>FY20E</b>
Net Debt/ Equity	1.1	0.8	0.7	0.6	0.5
Net Debt/EBIDTA	1.8	1.6	1.6	1.3	1.1
Working Cap Cycle (days)	94.1	95.5	97.0	97.3	97.4

<b>Growth (%)</b>	<b>FY16</b>	<b>FY17</b>	<b>FY18E</b>	<b>FY19E</b>	<b>FY20E</b>
Revenue	14.7	13.1	19.6	23.1	24.1
EBITDA	1.9	12.2	7.5	24.4	23.7
EBIT	1.0	9.9	6.4	26.6	25.6
PAT	6.7	17.3	9.2	35.5	31.9

<b>Quarterly (Rs mn)</b>	<b>Q3FY17</b>	<b>Q4FY17</b>	<b>Q1FY18</b>	<b>Q2FY18</b>	<b>Q3FY18</b>
Revenue	4,251	5,837	3,988	5,156	5,664
EBITDA	583	912	516	683	741
<b>EBITDA Margin (%)</b>	<b>13.7</b>	<b>15.6</b>	<b>12.9</b>	<b>13.2</b>	<b>13.1</b>
PAT	222	528	160	232	292
<b>EPS (Rs)</b>	<b>2.2</b>	<b>5.2</b>	<b>1.6</b>	<b>2.3</b>	<b>2.9</b>

Source: Company, Emkay Research

<b>Shareholding Pattern (%)</b>	<b>Dec-16</b>	<b>Mar-17</b>	<b>Jun-17</b>	<b>Sep-17</b>	<b>Dec-17</b>
Promoters	72.4	70.4	70.4	70.4	70.4
FIIIs	1.5	1.5	2.0	2.4	6.2
DIIIs	6.9	10.8	11.0	11.5	9.9
Public and Others	19.2	17.2	16.5	15.8	13.6


Source: Capitaline

## RECOMMENDATION HISTORY TABLE

Date	Closing Price	TP	Period (months)	Rating	Analyst
30-Jan-18	221	327	12m	Buy	John Perinchery
14-Dec-17	259	327	12m	Buy	John Perinchery
27-Nov-17	277	327	12m	Buy	John Perinchery
18-Oct-17	214	282	12m	Buy	John Perinchery

Source: Company, Emkay Research

## RECOMMENDATION HISTORY CHART



Source: Bloomberg, Company, Emkay Research

## Emkay Rating Distribution

BUY	Expected total return (%) (Stock price appreciation and dividend yield) of over 25% within the next 12-18 months.
ACCUMULATE	Expected total return (%) (Stock price appreciation and dividend yield) of over 10% within the next 12-18 months.
HOLD	Expected total return (%) (Stock price appreciation and dividend yield) of upto 10% within the next 12-18 months.
REDUCE	Expected total return (%) (Stock price depreciation) of upto (-) 10% within the next 12-18 months.
SELL	The stock is believed to underperform the broad market indices or its related universe within the next 12-18 months.

Completed Date:

Dissemination Date:

Sources for all charts and tables are Emkay Research unless otherwise specified.

### GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX). EGFSL along with its subsidiaries offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management, insurance broking and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com)

EGFSL is registered as Research Analyst with SEBI bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years, except that NSE had disabled EGFSL from trading on October 05, October 08 and October 09, 2012 for a manifest error resulting into a bonafide erroneous trade on October 05, 2012. However, SEBI and Stock Exchanges have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would subject EGFSL or its group companies to any registration or licensing requirement within such jurisdiction. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be used by private customers in United Kingdom. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

- This publication has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research publication relating to any issuer.

- Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets

**Disclaimer for U.S. persons only:** This research report is a product of Emkay Global Financial Services Limited (Emkay), which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account. This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a-6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors.



**GENERAL DISCLOSURE/DISCLAIMER BY DBS BANK LTD AS DISTRIBUTOR OF THE RESEARCH REPORT**

This report is solely intended for the clients of DBS Bank Ltd, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBS Bank Ltd.

The research set out in this report is based on information obtained from sources believed to be reliable, but we (which collectively refers to DBS Bank Ltd, its respective connected and associated corporations, affiliates and their respective directors, officers, employees and agents (collectively, the "DBS Group") have not conducted due diligence on any of the companies, verified any information or sources or taken into account any other factors which we may consider to be relevant or appropriate in preparing the research. Accordingly, we do not make any representation or warranty as to the accuracy, completeness or correctness of the research set out in this report. Opinions expressed are subject to change without notice. This research is prepared for general circulation. Any recommendation contained in this document does not have regard to the specific investment objectives, financial situation and the particular needs of any specific addressee. This document is for the information of addressees only and is not to be taken in substitution for the exercise of judgement by addressees, who should obtain separate independent legal or financial advice. The DBS Group accepts no liability whatsoever for any direct, indirect and/or consequential loss (including any claims for loss of profit) arising from any use of and/or reliance upon this document and/or further communication given in relation to this document. This document is not to be construed as an offer or a solicitation of an offer to buy or sell any securities. The DBS Group, along with its affiliates and/or persons associated with any of them may from time to time have interests in the securities mentioned in this document. The DBS Group, may have positions in, and may effect transactions in securities mentioned herein and may also perform or seek to perform broking, investment banking and other banking services for these companies. Any valuations, opinions, estimates, forecasts, ratings or risk assessments herein constitutes a judgment as of the date of this report, and there can be no assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments. The information in this document is subject to change without notice, its accuracy is not guaranteed, it may be incomplete or condensed, it may not contain all material information concerning the company (or companies) referred to in this report and the DBS Group is under no obligation to update the information in this report. This publication has not been reviewed or authorized by any regulatory authority in Singapore, Hong Kong or elsewhere. There is no planned schedule or frequency for updating research publication relating to any issuer.

The valuations, opinions, estimates, forecasts, ratings or risk assessments described in this report were based upon a number of estimates and assumptions and are inherently subject to significant uncertainties and contingencies. It can be expected that one or more of the estimates on which the valuations, opinions, estimates, forecasts, ratings or risk assessments were based will not materialize or will vary significantly from actual results. Therefore, the inclusion of the valuations, opinions, estimates, forecasts, ratings or risk assessments described herein IS NOT TO BE RELIED UPON as a representation and/or warranty by the DBS Group (and/or any persons associated with the aforesaid entities), that: (a) such valuations, opinions, estimates, forecasts, ratings or risk assessments or their underlying assumptions will be achieved, and (b) there is any assurance that future results or events will be consistent with any such valuations, opinions, estimates, forecasts, ratings or risk assessments stated therein. Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets. Any assumptions made in this report that refers to commodities, are for the purposes of making forecasts for the company (or companies) mentioned herein. They are not to be construed as recommendations to trade in the physical commodity or in the futures contract relating to the commodity referred to in this report.

DBSVUSA, a US-registered broker-dealer, does not have its own investment banking or research department, has not participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months and does not engage in market-making.

**ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)**

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associate<sup>1</sup> does not serve as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate does not have financial interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associate is defined as (i) the spouse, or any minor child (natural or adopted) or minor step-child, of the analyst; (ii) the trustee of a trust of which the analyst, his spouse, minor child (natural or adopted) or minor step-child, is a beneficiary or discretionary object; or (iii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.



**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):**

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

1. EGFSL, its subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of February 6, 2018
2. EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Research Report  
**Disclosure of previous investment recommendation produced:**
3. EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
4. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have any material conflict of interest in the securities recommended in this report as of February 6, 2018.
5. EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's does not have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the February 6, 2018
6. EGFSL, its subsidiaries and/or other affiliates and Research Analyst have not received any compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
7. EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst have not received any compensation or other benefits from securities recommended in this report (subject company) or third party in connection with the research report.
8. Securities recommended in this report (Subject Company) has not been client of EGFSL, its subsidiaries and/or other affiliates and/or and Research Analyst during twelve months preceding the February 6, 2018

**COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY DBS BANK LTD AS DISTRIBUTOR OF THE RESEARCH REPORT**

1. DBS Bank Ltd., DBS HK, DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), DBSV HK or their subsidiaries and/or other affiliates do not have a proprietary position in the securities recommended in this report as of 31 July 2017.
2. Neither DBS Bank Ltd, DBS HK nor DBSV HK market makes in equity securities of the issuer(s) or company(ies) mentioned in this Research Report.

**Compensation for investment banking services:**

3. DBSVUSA, does not have its own investment banking or research department, nor has it participated in any public offering of securities as a manager or co-manager or in any other investment banking transaction in the past twelve months. Any US persons wishing to obtain further information, including any clarification on disclosures in this disclaimer, or to effect a transaction in any security discussed in this document should contact DBSVUSA exclusively.

**Disclosure of previous investment recommendation produced:**

4. DBS Bank Ltd. DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by DBS Bank Ltd. DBS Vickers Securities (Singapore) Pte Ltd ("DBSVS"), their subsidiaries and/or other affiliates in the preceding 12 months.

**RESTRICTIONS ON DISTRIBUTION**

General	This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.
Australia	This report is not for distribution into Australia.
Hong Kong	This report is not for distribution into Hong Kong.
Indonesia	This report is being distributed in Indonesia by PT DBS Vickers Sekuritas Indonesia.
Malaysia	This report is not for distribution into Malaysia.
Singapore	This report is distributed in Singapore by DBS Bank Ltd (Company Regn. No. 16800306E) or DBSVS (Company Regn. No. 1860024G) both of which are Exempt Financial Advisers as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. DBS Bank Ltd and/or DBSVS, may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an agreement under Regulation 32C of the financial Advisers Regulations. Singapore recipients should contact DBS Bank Ltd at 6327 2288 for matters arising from, or in connection with the report.
Thailand	This report is being distributed in Thailand by DBS Vickers Securities (Thailand) Co Ltd.
United Kingdom	This report is disseminated in the United Kingdom by DBS Vickers Securities (UK) Ltd, ("DBSVUK"). DBSVUK is authorised and regulated by the Financial Conduct Authority in the United Kingdom. In respect of the United Kingdom, this report is solely intended for the clients of DBSVUK, its respective connected and associated corporations and affiliates only and no part of this document may be (i) copied, photocopied or duplicated in any form or by any means or (ii) redistributed without the prior written consent of DBSVUK. This communication is directed at persons having professional experience in matters relating to investments. Any investment activity following from this communication will only be engaged in with such persons. Persons who do not have professional experience in matters relating to investments should not rely on this communication.
Dubai International Financial Centre	This research report is being distributed by DBS Bank Ltd., (DIFC Branch) having its office at PO Box 506538, 3rd Floor, Building 3, East Wing, Gate Precinct, Dubai International Financial Centre (DIFC), Dubai, United Arab Emirates. DBS Bank Ltd., (DIFC Branch) is regulated by The Dubai Financial Services Authority. This research report is intended only for professional clients (as defined in the DFSA rulebook) and no other person may act upon it.
United Arab Emirates	This report is provided by DBS Bank Ltd (Company Regn. No. 196800306E) which is an Exempt Financial Adviser as defined in the Financial Advisers Act and regulated by the Monetary Authority of Singapore. This report is for information purposes only and should not be relied upon or acted on by the recipient or considered as a solicitation or inducement to buy or sell any financial product. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situation, or needs of individual clients. You should contact your relationship manager or investment adviser if you need advice on the merits of buying, selling or holding a particular investment. You should note that the information in this report may be out of date and it is not represented or warranted to be accurate, timely or complete. This report or any portion thereof may not be reprinted, sold or redistributed without our written consent.
United States	DBSVUSA did not participate in its preparation. The research analyst(s) named on this report are not registered as research analysts with FINRA and are not associated persons of DBSVUSA. The research analyst(s) are not subject to FINRA Rule 2241 restrictions on analyst compensation, communications with a subject company, public appearances and trading securities held by a research analyst. This report is being distributed in the United States by DBSVUSA, which accepts responsibility for its contents. This report may only be distributed to Major U.S. Institutional Investors (as defined in SEC Rule 15a-6) and to such other institutional investors and qualified persons as DBSVUSA may authorize. Any U.S. person receiving this report who wishes to effect transactions in any securities referred to herein should contact DBSVUSA directly and not its affiliate.
Other jurisdictions	In any other jurisdictions, except if otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions.

**Emkay Global Financial Services Ltd.**

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: [www.emkayglobal.com](http://www.emkayglobal.com)

**SINGAPORE****DBS Bank Ltd**

Contact: Janice Chua  
12 Marina Boulevard, Marina Bay Financial Centre Tower 3  
Singapore 018982  
Tel. 65-6878 8888  
Fax: 65 65353 418  
e-mail: equityresearch@dbs.com  
Company Regn. No. 196800306E

---

**THAILAND****DBS Vickers Securities (Thailand) Co Ltd**

Contact: Chanpen Sirithanarattanakul  
989 Siam Piwat Tower Building,  
9<sup>th</sup>, 14<sup>th</sup>-15<sup>th</sup> Floor  
Rama 1 Road, Pathumwan,  
Nagkok Thailand 10330  
Tel. 66 2 857 7831  
Fax: 66 2 658 1269  
e-mail: research@th.dbs.com  
Company Regn. No 0105539127012  
Securities and Exchange Commission, Thailand

---

**INDONESIA****PT DBS Vickers Sekuritas (Indonesia)**

Contact: Maynard Priajaya Arif  
DBS Bank Tower  
Ciputra World 1, 32/F  
Jl. Prof. Dr. Satrio Kav. 3-5  
Jakarta 12940, Indonesia  
Tel. 62 21 3003 4900  
Fax: 62 21 3003 4943  
e-mail: research@id.dbsvickers.com

---



John Perinchery, CMA., CA

john.perinchery@emkayglobal.com

+91 22 66121374